RayKnowChina Research Map
Shortlist0

Wenzhou Medical University

温州医科大学

WenzhouUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.7%Leads under 1 in 100 of China's research papers on NPC

Led 17 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
17
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 442025
ThemesRadiotherapy techniqueImaging & AIInduction / concurrent chemotherapy

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
1.0%Leads about 1 in 97 of China's research papers on ESCC

Led 30 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
30
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025
ThemesMolecular markers & genomicsImaging & AIRadiotherapy
Papers it led5
  1. Deep learning assists detection of esophageal cancer and precursor lesions in a prospective, randomized controlled study.2024Science translational medicineRCT
  2. Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010.2023The Journal of thoracic and cardiovascular surgeryRCT
  3. PPDPF promotes the progression of esophageal squamous cell carcinoma via c-Myc/CD24 axis.2025Journal for immunotherapy of cancerFree full text
  4. Identifying risk factors and evaluating therapeutic interventions for anastomotic recurrence in postoperative esophageal squamous cell carcinoma.2025BMC cancerFree full text
  5. Deep learning-based prediction of enhanced CT scans for lymph node metastasis in esophageal squamous cell carcinoma.2025Japanese journal of radiology
Trials on ClinicalTrials.gov4
  1. Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell CarcinomaRecruitingNCT06342167Study sitePhase 2Start 2024-03
  2. Study of Neo-adjuvant Chemoradiotherapy Followed by Minimally Invasive Esophagectomy for Squamous Cell Esophageal CancerStatus unknownNCT02188615Lead sponsorPhase 2Start 2011-06
  3. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
  4. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.5%Leads about 1 in 68 of China's research papers on HCC

Led 219 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
2
Research papers it led
219
Trials it led
7
Share of China's trials
0.5%
Share of the world's papers
0.8%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 112025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Papers it led5
  1. Efficacy analysis of TACE in combination with anlotinib and sintilimab in the treatment of unresectable hepatocellular carcinoma.2025Scientific reportsRCTFree full text
  2. A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation.2021Journal of experimental & clinical cancer research : CRRCTFree full text
  3. CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma.2023Journal for immunotherapy of cancerFree full text
  4. Digital pathology-based prognostic model for hepatocellular carcinoma: Integrating pathomics signatures with clinical parameters for recurrence prediction and biological interpretation.2026Computer methods and programs in biomedicine
  5. Ablation for hepatocellular carcinoma in hepatitis B-related recompensated vs. compensated cirrhosis.2026European radiology
Trials on ClinicalTrials.gov6
  1. Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular CarcinomaRecruitingNCT07495735Lead sponsorStart 2026-03
  2. The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related ToxicitiesRecruitingNCT07381634Lead sponsorPhase 2Start 2026-04
  3. Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCCNot yet recruitingNCT07596134Study siteN/AStart 2026-10
  4. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionRecruitingNCT07170345Study siteStart 2025-09
  5. 29-Gene Liver Cancer Subtype and Immunotherapy EffectivenessNot yet recruitingNCT07100236Study siteStart 2025-08
  6. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.5%Leads about 1 in 67 of China's research papers on Stomach cancer

Led 146 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
4
Research papers it led
146
Trials it led
6
Share of China's trials
0.4%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025
ThemesSurgeryImaging & AINutrition & recovery

Hospitals counted here

  1. First Affiliated Hospital of Wenzhou Medical University55
  2. Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University26
  3. Taizhou Hospital, Wenzhou Medical University17
  4. Quzhou Affiliated Hospital of Wenzhou Medical University Counted in the group total6
  5. Affiliated Hospital of Wenzhou Medical University5
  6. Fifth Affiliated Hospital of Wenzhou Medical University Counted in the group total5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Prognostic impact of a 3-week multimodal prehabilitation program on frail elderly patients undergoing elective gastric cancer surgery: a randomized trial.2024BMC gastroenterologyRCTFree full text
  2. Effects of esketamine on postoperative fatigue syndrome in patients after laparoscopic resection of gastric carcinoma: a randomized controlled trial.2024BMC anesthesiologyRCTFree full text
  3. Evaluation the benefits of additional radiotherapy for gastric cancer patients after D2 resection using CT based radiomics.2023La Radiologia medicaRCT
  4. A Dual-phase Enhanced CT-based Nomogram for Predicting the Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.2026Academic radiology
  5. CT-based delta-radiomics nomogram to assess tumor regression grade in locally advanced gastric cancer patients following neoadjuvant chemotherapy.2026Abdominal radiology (New York)
Trials on ClinicalTrials.gov6
  1. Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric CancerNot yet recruitingNCT07828899Lead sponsorN/AStart 2026-10
  2. Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic CancerNot yet recruitingNCT07394205Lead sponsorEarly phase 1Start 2026-09
  3. Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled TrialRecruitingNCT07586384Lead sponsorN/AStart 2025-11
  4. Gastric Cancer Marker Detection and Its Kit DevelopmentRecruitingNCT05010863Lead sponsorStart 2021-01
  5. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  6. Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated GastroscopyRecruitingNCT07104214Study siteStart 2025-08

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
0.7%Leads under 1 in 100 of China's research papers on Retinoblastoma

Led 2 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Eye Hospital of Wenzhou Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
0.9%Leads under 1 in 100 of China's research papers on Chordoma ▼ from 2.3%

Led 1 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Random survival forests-based survival prediction for spinal chordomas.2025Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.4%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 8 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.0%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour

Led 5 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 112025

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.6%Leads under 1 in 100 of China's research papers on Neuroblastoma ▼ from 1.1%

Led 7 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.9%Leads under 1 in 100 of China's research papers on Myeloma

Led 15 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
15
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 112025
ThemesDiagnosis, MRD & riskCAR-T & cell therapyRelapse & resistance

Hospitals counted here

  1. First Affiliated Hospital of Wenzhou Medical University6
  2. Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University2
  3. Taizhou Hospital, Wenzhou Medical University2
  4. Third Affiliated Hospital of Wenzhou Medical University Counted in the group total1
  5. Quzhou Affiliated Hospital of Wenzhou Medical University Counted in the group total1
  6. Dongyang Hospital, Wenzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. The efficacy and safety of anti-CD38 monoclonal antibodies in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.2026Current research in translational medicine
  2. Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma.2023Clinical lymphoma, myeloma & leukemia
  3. Characteristics of inpatients with newly diagnosed multiple myeloma in hematology, nephrology, and orthopedic departments.2023Annals of hematology
  4. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.2021Frontiers in immunologyFree full text
  5. Comprehensive analysis of exosome-related gene signature in multiple myeloma prognosis and immune microenvironment evaluation.2025Cancer immunology, immunotherapy : CIIFree full text
Trials on ClinicalTrials.gov6
  1. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  2. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  3. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07258511Study sitePhase 3Start 2026-02
  4. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  5. Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma PatientsRecruitingNCT06520176Study sitePhase 3Start 2024-08
  6. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.9%Leads under 1 in 100 of China's research papers on B-ALL New since 2021

Led 2 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
1
Share of China's trials
0.4%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025
ThemesPhiladelphia chromosome & genetics

Hospitals counted here

  1. First Affiliated Hospital of Wenzhou Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
0.0%Leads none of China's research papers on HLH

Led 0 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
1.0%Leads under 1 in 100 of China's research papers on Beta thalassaemia

Led 3 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Wenzhou Medical University2
  2. Taizhou Hospital, Wenzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
1.7%Leads about 1 in 61 of China's research papers on NMOSD ▼ from 3.5%

Led 8 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025
ThemesAntibodies & diagnosisAcute attack treatmentRelapse prevention

Hospitals counted here

  1. First Affiliated Hospital of Wenzhou Medical University5
  2. Wenzhou Central Hospital, Wenzhou Medical University Counted in the group total1
  3. Fifth Affiliated Hospital of Wenzhou Medical University Counted in the group total1
  4. Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
0.8%Leads under 1 in 100 of China's research papers on IgG4-RD

Led 2 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025
ThemesDiagnosis & look-alikesLung & chestKidney, retroperitoneum & vessels

Hospitals counted here

  1. First Affiliated Hospital of Wenzhou Medical University Counted in the group total1
  2. People's Hospital, Wenzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
1.2%Leads about 1 in 83 of China's research papers on Myasthenia gravis ▼ from 2.5%

Led 6 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025
ThemesBiologic & complement drugsAntibodies & diagnosisStandard immunotherapy

Hospitals counted here

  1. First Affiliated Hospital of Wenzhou Medical University4
  2. Third Affiliated Hospital of Wenzhou Medical University Counted in the group total1
  3. Wenzhou Central Hospital Counted in the group total1
  4. Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
1.1%Leads about 1 in 88 of China's research papers on Anti-NMDA receptor encephalitis New since 2021

Led 3 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University2
  2. Taizhou Hospital, Wenzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
1.0%Leads about 1 in 99 of China's research papers on Idiopathic pulmonary fibrosis

Led 10 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
1
Share of China's trials
1.4%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.8%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis ▲ from 0.3%

Led 6 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.09%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025

Hospitals counted here

  1. First Affiliated Hospital of Wenzhou Medical University5
  2. Eye Hospital of Wenzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
0.9%Leads under 1 in 100 of China's research papers on Duchenne muscular dystrophy New since 2021

Led 2 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.08%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

Hospitals counted here

  1. Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
1.2%Leads about 1 in 82 of China's research papers on Behçet disease

Led 3 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 222025

PubMed searchClinicalTrials.gov

Alport syndrome

Alport 综合征
3.5%Leads about 1 in 29 of China's research papers on Alport syndrome

Led 2 of 58 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University1
  2. Taizhou Hospital, Wenzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
1.2%Leads about 1 in 82 of China's research papers on IgA nephropathy

Led 9 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 0020242025: 222025

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
2.3%Leads about 1 in 43 of China's research papers on Primary biliary cholangitis

Led 7 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 3320242025: 002025

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
0.0%Leads none of China's research papers on Primary sclerosing cholangitis

Led 0 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Leber hereditary optic neuropathy

Leber 遗传性视神经病变
7.7%Leads about 1 in 13 of China's research papers on Leber hereditary optic neuropathy ▼ from 9.8%

Led 4 of 52 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (21.1%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.3%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. Eye Hospital of Wenzhou Medical University3
  2. First Affiliated Hospital of Wenzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov